Maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta 2-agonist
Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) is recommended as an option for the treatment of COPD with the following restriction:
Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy.
Reason for decision:
Suitable for initiation in primary care in line with restrictions